Breaking News

MedPharm to Support Mosanna Therapeutics in the Development of MOS-118

New drug aims to tackle Metabolic Obstructive Sleep Apnea.

Author Image

By: Charlie Sternberg

Associate Editor

MedPharm, a global provider of contract topical and transdermal formulation development and manufacturing services, has announced that it will support Swiss Biotech company, Mosanna Therapeutics, in the development of a nasal spray (MOS-118) aimed at treating Metabolic Obstructive Sleep Apnea (MOSA).   The collaboration will focus on advancing MOS-118 into clinical development. Mosanna is developing MOS-118 to prevent the airway from collapsing during sleep in a disease that affects up to 1 bi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters